A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

February 1, 2022

Primary Completion Date

March 11, 2024

Study Completion Date

May 5, 2027

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Loncastuximab tesirine

Intravenous (IV) infusion

DRUG

Prednisone

Orally via tablet or capsule

DRUG

Rituximab

Intravenous (IV) infusion

DRUG

Cyclophosphamide

Intravenous (IV) infusion

DRUG

Doxorubicin

Intravenous (IV) infusion

DRUG

Vincristine

Intravenous (IV) infusion

Trial Locations (1)

University Hospitals Cleveland Medical Center, Cleveland